Kuros Biosciences Ltd. (KURN) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months

Poor long term growth as Net Sales has grown by an annual rate of -44.92% and Operating profit at -0.77% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times

Risky -

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CHF 1,216 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.19

Return on Equity

-40.21%

Price to Book

15.86

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Dec 2013)

Net Profit:

-10 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

22.04%

6 Months

5.44%

1 Year

38.89%

2 Years

553.3%

3 Years

1744.37%

4 Years

1386.01%

5 Years

1265.71%

Kuros Biosciences Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-44.92%

EBIT Growth (5y)

-0.77%

EBIT to Interest (avg)

-4.29

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.24

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

16.34

EV to EBIT

-48.89

EV to EBITDA

-49.05

EV to Capital Employed

19.83

EV to Sales

1237.98

PEG Ratio

Dividend Yield

ROCE (Latest)

-40.56%

ROE (Latest)

-40.21%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'13 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2013 is 0.00% vs 0.00% in Dec 2012",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2013 is -142.50% vs -53.85% in Dec 2012",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'13",
        "Dec'12",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.10",
          "val2": "-5.60",
          "chgp": "-44.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.30",
          "val2": "1.30",
          "chgp": "76.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.70",
          "val2": "-4.00",
          "chgp": "-142.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-32,592.00%",
          "val2": "-22,332.00%",
          "chgp": "-1,026.00%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 125.00% vs 86.67% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 63.73% vs 30.14% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "75.60",
          "val2": "33.60",
          "chgp": "125.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2.60",
          "val2": "-2.60",
          "chgp": "200.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.20",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.60",
          "val2": "-2.60",
          "chgp": "-76.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.70",
          "val2": "-10.20",
          "chgp": "63.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-0.10%",
          "val2": "-158.90%",
          "chgp": "15.88%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'13 - YoY

Dec'13

Dec'12

Change(%)

Net Sales

0.30

Operating Profit (PBDIT) excl Other Income

-8.10

-5.60

-44.64%

Interest

2.30

1.30

76.92%

Exceptional Items

0.00

Consolidate Net Profit

-9.70

-4.00

-142.50%

Operating Profit Margin (Excl OI)

-32,592.00%

-22,332.00%

-1,026.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2013 is 0.00% vs 0.00% in Dec 2012

Consolidated Net Profit

YoY Growth in quarter ended Dec 2013 is -142.50% vs -53.85% in Dec 2012

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

75.60

33.60

125.00%

Operating Profit (PBDIT) excl Other Income

2.60

-2.60

200.00%

Interest

0.10

0.20

-50.00%

Exceptional Items

-4.60

-2.60

-76.92%

Consolidate Net Profit

-3.70

-10.20

63.73%

Operating Profit Margin (Excl OI)

-0.10%

-158.90%

15.88%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 125.00% vs 86.67% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 63.73% vs 30.14% in Dec 2023

All Annual Results

Company CV

About Kuros Biosciences Ltd.

Kuros Biosciences Ltd.

Pharmaceuticals & Biotechnology

Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.

Company Coordinates

Company Details

Wagistrasse 25 , SCHLIEREN None : 8952

Tel: 41 44 7334747

http://www.kuros.ch/

Registrar Details